Dexcom Stock

Dexcom Gross Profit

The Gross Profit of Dexcom (DXCM) as of Aug 25, 2026 is 2.80 B USD. In the previous year, Gross Profit was 2.44 B USD — a change of 14.92% (higher).

Gross Profit

2.80 BUSD

YoY

14.92%

Last updated:

Gross Profit of Dexcom is 2026 2.80 B USD. Gross Profit of Dexcom was 2025 2.44 B USD. It decreases by 14.92% higher compared to the previous year.

The Dexcom Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
663.90 M USD
Jan 1, 2019
931.50 M USD
Jan 1, 2020
1.28 B USD
Jan 1, 2021
1.68 B USD
Jan 1, 2022
1.88 B USD
Jan 1, 2023
2.29 B USD
Jan 1, 2024
2.44 B USD
Jan 1, 2025
2.80 B USD
The Dexcom Gross Profit history
YEARGross ProfitYoY
2.80 BUSD+14.92%
2.44 BUSD+6.52%
2.29 BUSD+21.55%
1.88 BUSD+12.06%
1.68 BUSD+31.28%
1.28 BUSD+37.42%
931.50 MUSD+40.31%
663.90 MUSD+34.91%
492.10 MUSD+30.05%
378.40 MUSD+35.92%
278.40 MUSD+57.91%
176.30 MUSD+76.12%
100.10 MUSD+114.81%
46.60 MUSD+30.01%
35.84 MUSD+94.35%
18.44 MUSD+403.77%
3.66 MUSD-166.21%
-5.53 MUSD-31.82%
-8.11 MUSD-7.74%
-8.79 MUSD
Access this data via the Eulerpool API

Dexcom Revenue

Dexcom Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
3.62 B USD
597.70 M USD
541.50 M USD
Jan 1, 2024
4.03 B USD
600.00 M USD
576.20 M USD
Jan 1, 2025
4.66 B USD
911.80 M USD
836.30 M USD
Jan 1, 2026 (e)
5.23 B USD
1.88 B USD
1.04 B USD
Jan 1, 2027 (e)
5.80 B USD
2.09 B USD
1.22 B USD
Jan 1, 2028 (e)
6.45 B USD
2.32 B USD
1.45 B USD
Jan 1, 2029 (e)
7.20 B USD
2.59 B USD
1.69 B USD
Jan 1, 2030 (e)
7.98 B USD
2.87 B USD
1.97 B USD

Dexcom Margins

Dexcom stock margins

The Dexcom margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dexcom. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dexcom.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
63.19 %
16.50 %
14.95 %
Jan 1, 2024
60.46 %
14.88 %
14.29 %
Jan 1, 2025
60.10 %
19.56 %
17.94 %
Jan 1, 2026 (e)
60.10 %
36.00 %
19.89 %
Jan 1, 2027 (e)
60.10 %
36.00 %
21.00 %
Jan 1, 2028 (e)
60.10 %
36.00 %
22.49 %
Jan 1, 2029 (e)
60.10 %
36.00 %
23.47 %
Jan 1, 2030 (e)
60.10 %
36.00 %
24.70 %

Dexcom Stock analysis

What does Dexcom do? Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dexcom stock

Gross Profit of Dexcom is 2.80 B USD in 2026.

Gross Profit of Dexcom changed from 2.44 B USD to 2.80 B USD, representing a 14.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Dexcom since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Dexcom historically and in real time.

Access this data via the Eulerpool API

Income Statement — Dexcom

All Key Metrics — Dexcom